P

PharmaCyte Biotech, Inc. Common Stock

XNAS · Laboratory Analytical Instruments · S&P 500

$0.62

-$0.01 (-1.94%) today

Open $0.64 High $0.66 Low $0.61 Vol 77K Avg $0.63

Related Stocks

Find similar stocks by technical condition — S&P 500 universe

Symbol Company Name Exchange Currency Category
LIMN Liminatus Pharma, Inc. Class A Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CMPX Compass Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
EXOZ eXoZymes Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PHGE BiomX Inc. XASE USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SANA Sana Biotechnology, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SGMO Sangamo Therapeutics, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
PCVX Vaxcyte, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
TECH Bio-Techne Corp. XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CELZ Creative Medical Technology Holdings, Inc. Common Stock XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
MGTX MeiraGTx Holdings plc Ordinary Shares XNAS USD BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

52-week price range

$0.00 $0.00

Price is 0.0% above its 52-week low and 0.0% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

  • Primary Exchange: XNAS
  • Market Cap: 8188079.4923
  • Address:
  • Category: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
  • Total Employees: 2
  • Listing Date: 2003-09-11